Sequoia Financial Advisors LLC Raises Stake in Illumina, Inc. (NASDAQ:ILMN)

Sequoia Financial Advisors LLC boosted its position in Illumina, Inc. (NASDAQ:ILMN) by 16.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,733 shares of the life sciences company’s stock after buying an additional 789 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Illumina were worth $766,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also bought and sold shares of ILMN. Versant Capital Management Inc lifted its position in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. Golden State Wealth Management LLC bought a new stake in Illumina in the fourth quarter valued at approximately $32,000. Assetmark Inc. lifted its position in Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Illumina in the fourth quarter valued at approximately $45,000. Finally, TD Private Client Wealth LLC lifted its position in Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after purchasing an additional 141 shares during the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ILMN. Hsbc Global Res downgraded Illumina from a “strong-buy” rating to a “hold” rating in a report on Friday, February 28th. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $177.00 to $140.00 in a report on Friday, February 7th. Stephens reissued an “overweight” rating and issued a $156.00 target price on shares of Illumina in a research note on Tuesday, March 11th. Guggenheim dropped their price objective on Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Finally, Barclays reaffirmed an “underweight” rating on shares of Illumina in a research report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Stock Performance

NASDAQ ILMN opened at $85.60 on Monday. The stock has a market capitalization of $13.56 billion, a PE ratio of -11.15, a P/E/G ratio of 1.60 and a beta of 1.17. The business has a 50 day simple moving average of $113.52 and a two-hundred day simple moving average of $129.86. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 1-year low of $80.18 and a 1-year high of $156.66.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts predict that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.